Clinical Trial Update: A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of T3011 in patients with nonmuscle-invasive bladder cancer who are BCG-unresponsive or BCG-exposed and chemotherapy-unresponsive is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• T3011

Snippet

Sponsor: ImmVira Pharma Co. Ltd | Conditions: Nonmuscle-invasive Bladder Cancer | Phase 2 | Status: RECRUITING